Crystal PharmaTech Collaborates with Freeslate for Solid Form Screening - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Crystal PharmaTech Collaborates with Freeslate for Solid Form Screening



Crystal Pharmatech, a leader in solid-state chemistry services for drug development, has selected Freeslate, a provider of high through put research solutions, for its CM Protégé PharmD System for polymorph, salt, co-crystal, and solubility screens of APIs.

The Freeslate PharmD System will be used to extend thepolymorph and solubility screens completed without increasing the time or resources required. Crystal Pharmatech will also serve as a reference site and demo lab for Freeslate, hosting customers and product demonstrations and participating in speaking engagements.

Freeslate's CM Protégé PharmD System brings high-throughput solid and solubility screening to a broader range of researchers with a fully automated platform. The system can evaluate up to 384 crystallization conditions per run to quickly turn around solid-form screening projects and save users valuable material through its ability to use approximately 1 g of API per solid-form screen. Solid forms can be analyzed by birefringence, x-ray powder diffraction, and Raman spectroscopy directly from the glass universal substrate without any manual manipulation of fragile crystals. Other analyses and experiments, such as solid form stability, can also be conducted directly on the glass universal substrate. Heating, cooling, and mixing on-deck allows for simultaneous slurry, precipitation, cooling, and evaporation experiments on a single platform.

The CM Protégé PharmD System uses Freeslate's Lab Execution and Analysis (LEA) software for library design, protocol development/execution, data analysis, and reporting. This allows users to design complex experiments quickly using its recipe-oriented approach. Using LEA, experimental conditions can be linked to analytical data for easy viewing and reporting.

Source: Crystal Pharmatech

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
27%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
8%
All of the above.
41%
No government involvement in patient treatment or drug development.
11%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?

Click here